Condition
Gliomas, Malignant
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (4)
Trial Status
Terminated2
Suspended1
Completed1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06270082Phase 1Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT05475522Not ApplicableSuspendedPrimary
Intraoperative Sonographically Versus Fluorescence-guided Resection of Contrast-enhancing Gliomas and Brain Metastases
NCT06640582Phase 1Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06562621Phase 1Completed
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
NCT04327011Phase 1Terminated
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Showing all 5 trials